Search, Find and Buy Antibodies, ELISA Kits and Proteins.
Loading Loading
Add to Basket
Order hotline:
phone +1 404 474 4654
fax +1 888 205 9894 (TF)
Details for Product No. ABIN271729

Leucine-Rich Repeat Kinase 2 (LRRK2) antibody

Request
Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms PARK8, RIPK7, ROCO2, AURA17, DARDARIN, Gm927, cI-46, AW561911, 4921513O20Rik, 9330188B09Rik, D630001M17Rik, LRRK2
Reactivity
»Alternatives Human
Host
»Alternatives Sheep
Clonality Polyclonal
Conjugate
»Alternatives Un-conjugated
Application
»Alternatives Immunohistochemistry (Frozen Sections) (IHC (fro))
Pubmed 10 references available
Catalog no. ABIN271729
Quantity 0.1 mL
Price
Contact our Customer Service for availability and price in your country.
Shipping to
Immunogen A synthetic peptide (lkrkrkilssddslrss, aa 946-962) as part of human LRRK2 proteinconjugated to the Blue Carrier Protein has been used as the immunogen.
Specificity Species Reactivity: This antiserum has been successfully tested in human. Other species have not yet beentested. Localization: Accession Number: LRRK2_HUMAN.
Cross-Reactivity Human
Alternative Name PARK8 / LRRK2
Background This gene is a member of the leucine-rich repeat kinase family and encodes a proteinwith an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, aDFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40domain. The protein is present largely in the cytoplasm but also associates with themitochondrial outer membrane. Mutations in this gene have been associated withParkinson disease-8. Alternate Names: anti-LRRK-2 antibody, anti-LRRK 2 antibody, anti-PARK8 antibody, anti-ROCO2antibody, anti-Dardarin antibody, biosensis. Related Diseases: Alzheimer's/ Parkinson's
Gene ID 120892
Restrictions For Research Use only
Buffer Reconstitute in 100 ul of sterile water. Centrifuge to remove any insoluble material. Preservative: No Preservative.
Ota, Suzuki, Nishikawa et al.: "Complete sequencing and characterization of 21,243 full-length human cDNAs." in: Nature genetics, Vol. 36, Issue 1, pp. 40-5, 2003 (PubMed).

Paisán-Ruíz, Jain, Evans et al.: "Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease." in: Neuron, Vol. 44, Issue 4, pp. 595-600, 2004 (PubMed).

Zimprich, Biskup, Leitner et al.: "Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology." in: Neuron, Vol. 44, Issue 4, pp. 601-7, 2004 (PubMed).

Nichols, Pankratz, Hernandez et al.: "Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease." in: Lancet, Vol. 365, Issue 9457, pp. 410-2, 2005 (PubMed).

Di Fonzo, Rohue, Ferreira et al.: "A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease." in: Lancet, Vol. 365, Issue 9457, pp. 412-5, 2005 (PubMed).

Gilks, Abou-Sleiman, Gandhi et al.: "A common LRRK2 mutation in idiopathic Parkinson's disease." in: Lancet, Vol. 365, Issue 9457, pp. 415-6, 2005 (PubMed).

Adams, van Netten, Schulzer et al.: "PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation." in: Brain : a journal of neurology, Vol. 128, Issue Pt 12, pp. 2777-85, 2005 (PubMed).

West, Moore, Biskup et al.: "Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, Issue 46, pp. 16842-7, 2005 (PubMed).

Gloeckner, Kinkl, Schumacher et al.: "The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity." in: Human molecular genetics, Vol. 15, Issue 2, pp. 223-32, 2006 (PubMed).

Galter, Westerlund, Carmine et al.: "LRRK2 expression linked to dopamine-innervated areas." in: Annals of neurology, Vol. 59, Issue 4, pp. 714-9, 2006 (PubMed).

Alternatives for antigen "Leucine-Rich Repeat Kinase 2 (LRRK2)", type "Antibodies"
Hosts (121), (49), (8), (3)
Reactivities (159), (91), (73), (40), (15), (13), (2)
Applications (145), (49), (47), (44), (39), (25), (20), (18), (16), (8), (2), (2), (1), (1), (1)
Conjugates (9), (9), (6), (4), (3), (3), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2)
Epitopes (32), (20), (18), (18), (12), (12), (8), (6), (5), (4), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1)
Beacon